Skip to main content
. 2007 Feb 7;13(5):732–739. doi: 10.3748/wjg.v13.i5.732

Figure 2.

Figure 2

Change from baseline in the number of CSBMs per week (wk 1-4) by treatment (ITT population). Footnote: bP = 0.0002 vs placebo; Mean number of CSBMs per week at baseline: tegaserod 0.36; placebo 0.31.